Akademik Veri Yönetim Sistemi
21. Ulusal Cerrahi Kongresi, Antalya, Türkiye, 11 - 15 Nisan 2018, ss.644
The effectiveness of screening practices in breast cancer is known. However, are these screening applications effective in our
country? In order to study this issue, our hospital was selected as the screening hospital. The cases that had been operated before and after the selection were compared in our hospital.
A total of 288 patients were included. Of these 288 patients, 285 (99%) were female and 3 were male. The average age of the
patients who were admitted was 56.70±13.23 (55,17-58,24). When the breast with the involvement was examined; it was seen
that 153 were left breast and 135 were right breast. When the tumor size was examined, it was found that 159 (55.2%) patients
had a tumor size of<2 cm, 116 (40.3%) patients had 2-5 cm, and 13 (4.5) patients had a tumor size of>5 cm. 101 patients (35.1%
4) had stage 1, 78 patients (27.1%) had stage 2A, 45 patients (15.6%) had stage 2B, 38 patients (13.2%) had stage 3A, 23 patients
(8%) had stage 3C, and 1 patient (0.3%) had stage 4.
203 (70%) patients were pre-screening patient group and were referred to as Group A. 85 (30%) were post-screening group and
were called Group B.
Of the 203 patients in group A, the mass in 100 patients was left-localized. When the size of the tumor in group A was examined,
it was determined that 107 (52.7%) patients had tumor sizes of<2 cm, 86 (42.4%) patients 2-5 cm and 10 (4.9%) patients with a
tumor size of>5 cm. It was detected that 67 patients (33%) had stage 1, 55 patients (27.1%) had stage 2A, 31 patients (15.3%) had
stage 2B, 29 patients (14.3%) had stage 3A, 21 patients (10.3%) had stage 3C, and 1 patient (0.04%) had stage 4.
Of the 85 patients in group B, 53 (62.4%) patients had left breast localized mass. When tumor size was examined, it was found
that 52 (61.2%) patients had a size of 2 cm, 30 (34.2%) patients had 2-5 cm and 3 (3.5%) patients had a size of>5 cm. It was found
that 36 (42.4%) patients were stage 1, 23 (27.1%) were stage 2A, 14 (16.5%) patients were stage 2B, 9 (10.6%) patients were stage
3A and 3 (3.5%) patients were stage 3C.
There was no difference between the two groups in terms of all data.